keytruda
FDA to review MSD’s Keytruda as a first-line lung cancer treatment
September 7, 2016Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo
The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …
Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial
September 1, 2016Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq
Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …
FDA approves MSD’s Keytruda for head and neck cancer treatment
August 8, 2016Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …
Opdivo and Keytruda set for India launches by end of year
August 8, 2016Sales and Marketing India, keytruda, launch, opdivo
Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …
MSD scores EU approval for Keytruda in lung cancer
August 3, 2016Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer
MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …
UK medical charity sells part of interest in MSD’s Keytruda for $150 million
July 15, 2016Research and Development, Sales and Marketing MSD, Merck, keytruda
UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
MSD gets CHMP positive opinion for keytruda to treat advanced lung cancer
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing CHMP, EMA, MSD, Merck & Co, keytruda, lung cancer
MSD (Merck & Co) said its anti-programmed death-1 (PD-1) therapy, Keytruda (pembrolizumab) to treat lung cancer has secured a positive …
Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer
June 17, 2016Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer
US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …
MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival
June 8, 2016Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda
Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
MSD receives fourth Breakthrough Therapy Designation for Keytruda
April 19, 2016Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
Merck says US FDA to review its Keytruda for head & neck cancer
April 14, 2016Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda
The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …
Merck says US FDA accepts its sBLA for Keytruda
March 8, 2016Manufacturing and Production, Research and Development Merck & Co, US FDA, keytruda, melanoma
US pharma giant Merck & Co said the US Food and Drug Administration (FDA) has accepted for review a new …
BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer
January 13, 2016Research and Development MSD, immunotherapy, keytruda, pembrolizumab
Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …
MSD’s Keytruda impresses in lung cancer chemotherapy trial
December 21, 2015Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab
MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
Eisai’s Halaven shown to restrict further cancer metastasis
December 11, 2015Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda
New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
